The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids.
“These rare cannabinoids offer specific health benefits that are better than CBD,” O’Neill said.
